Ionis Pharmaceuticals IONS Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Ionis Pharmaceuticals (IONS) reported accretion (amortization) of discounts and premiums, investments of $6.19M in Q1 2026.
- How has Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Ionis Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 12.9% year-over-year, from $7.11M to $6.19M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- The periodic adjustment of investment values to account for purchase price differences from face value.
- How do you interpret accretion (amortization) of discounts and premiums, investments?
- Reflects the yield profile of the company's investment portfolio and interest rate environment impacts.
- How does accretion (amortization) of discounts and premiums, investments compare across companies?
- Common for companies with large cash and marketable securities portfolios managed for yield.